What is the recommended dosage of Ambroxol (Syp Ambroxl) for pediatric patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ambroxol Syrup Dosage for Pediatric Patients

For pediatric patients with acute and chronic respiratory diseases, ambroxol should be dosed at 1.5-2.0 mg/kg body weight per day, divided into 2-3 doses, with a typical daily dose of 30 mg for younger children administered as oral syrup. 1, 2

Age-Specific Dosing Recommendations

Infants and Young Children (1 month to 2 years)

  • 1.5-2.0 mg/kg/day divided into 2-3 doses 2
  • Ambroxol has been shown to be efficacious and well-tolerated in children as young as 1 month old 1
  • The syrup formulation is preferred for this age group due to ease of administration 1

Children (2-13 years)

  • 30 mg daily (typically given as 2 sachets or divided doses) 3
  • This can be administered as 15 mg twice daily or adjusted based on the 1.5-2.0 mg/kg/day guideline 3, 2
  • Treatment duration typically ranges from 10 days for acute conditions 3, 2

Clinical Considerations

Formulation and Administration

  • Oral syrup is the preferred formulation for pediatric patients who may have difficulty swallowing tablets 1
  • The medication can be given without regard to meals, though administration with food may improve tolerability 1

Treatment Duration

  • Acute respiratory infections: 10 days 3, 2
  • Chronic respiratory conditions may require longer treatment courses based on clinical response 1

Efficacy Timeline

  • Clinical improvement in cough, chest pathological signs, and radiographic findings occurs more rapidly with ambroxol compared to placebo or other mucolytics 2, 3
  • Ambroxol demonstrates faster onset of action compared to acetylcysteine in pediatric patients with spastic bronchitis 3

Safety Profile

  • Ambroxol is well-tolerated across all pediatric age groups, including early infancy 1, 2
  • The favorable benefit-risk profile established in adults extends to the pediatric population 1
  • No significant adverse effects were reported in clinical studies involving nearly 1,300 pediatric patients 1

Common Pitfalls to Avoid

  • Do not underdose based on age alone—use weight-based dosing (1.5-2.0 mg/kg/day) for optimal efficacy 2
  • Ensure adequate treatment duration—premature discontinuation may result in incomplete resolution of symptoms 3, 2
  • Consider combination therapy—ambroxol can be safely combined with antibiotics for acute lower respiratory tract infections, potentially accelerating clinical improvement 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.